Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)

References

• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1–6. doi: 10.1001/jama.2020.4006.
   Web of Science ®Google Scholar
• Parisi R, Symmons DP, Griffiths CE, Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) Project Team, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385. doi: 10.1038/jid.2012.339.
   PubMed Web of Science ®Google Scholar
• Pezzolo E, Cazzaniga S, Colombo P, et al. Psoriasis incidence and lifetime prevalence: suggestion for a higher mortality rate in older age-classes among psoriatic patients compared to the general population in Italy. Acta Derm Venereol. 2019;99(4):400–403. doi: 10.2340/00015555-3130.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Villanova F, Nestle FO. Psoriasis. Cold Spring Harb Perspect Med. 2014;4(8):a015354. doi: 10.1101/cshperspect.a015354.
   PubMed Web of Science ®Google Scholar
• Carvalho AV, Romiti R, Souza CD, et al. Psoriasis comorbidities: complications and benefits of immunobiological treatment. An Bras Dermatol. 2016;91(6):781–789. doi: 10.1590/abd1806-4841.20165080.
   PubMed Web of Science ®Google Scholar
• Kolli SS, Amin SD, Pona A, et al. Psychosocial impact of psoriasis: a review for dermatology residents. Cutis. 2018;102(5S):21–25.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis: a meta-analysis. JAMA Dermatol. 2020;156(3):258–269. doi: 10.1001/jamadermatol.2019.4029.
   PubMed Web of Science ®Google Scholar
• Belinchón I, Rivera R, Blanch C, et al. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European Union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–2367. doi: 10.2147/PPA.S117006.
   PubMed Web of Science ®Google Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi: 10.1007/s00403-010-1080-1.
   PubMed Web of Science ®Google Scholar
• Vide J, Magina S. Moderate to severe psoriasis treatment challenges through the era of biological drugs. An Bras Dermatol. 2017;92(5):668–674. doi: 10.1590/abd1806-4841.20175603.
   PubMed Web of Science ®Google Scholar
• Azhar A, Zaayman M, Silfvast-Kaiser A, et al. Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: patient adherence, satisfaction, and preferences. Dermatol Ther. 2021;34(1):e14486. doi: 10.1111/dth.14486.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Blauvelt A, Papp KA, UNCOVER-1 Study Group; UNCOVER-2 Study Group; UNCOVER-3 Study Group., et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345–356. doi: 10.1056/NEJMoa1512711.
   PubMed Web of Science ®Google Scholar
• Papp KA, Leonardi CL, Blauvelt A, et al. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3). Br J Dermatol. 2018;178(3):674–681. doi: 10.1111/bjd.16050.
   PubMed Web of Science ®Google Scholar
• Leonardi CL, Blauvelt A, Sofen HL, et al. Rapid improvements in health-related quality of life and itch with ixekizumab treatment in randomized phase 3 trials: results from UNCOVER-2 and UNCOVER-3. J Eur Acad Dermatol Venereol. 2017;31(9):1483–1490. doi: 10.1111/jdv.14211.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Maari C, Philipp S, et al. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study. J Am Acad Dermatol. 2018;79(5):824–830.e2. doi: 10.1016/j.jaad.2018.05.032.
   PubMed Web of Science ®Google Scholar
• Leonardi C, Reich K, Foley P, et al. Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials. Dermatol Ther. 2020;10(3):431–447. doi: 10.1007/s13555-020-00367-x.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Lebwohl MG, Mabuchi T, et al. Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial. J Am Acad Dermatol. 2021;85(2):360–368. doi: 10.1016/j.jaad.2020.11.022.
   PubMed Web of Science ®Google Scholar
• Damiani G, Conic RRZ, Pigatto PDM, Young Dermatologists Italian Network, et al. From randomized clinical trials to real life data. An Italian clinical experience with ixekizumab and its management. Dermatol Ther. 2019;32(3):e12886. doi: 10.1111/dth.12886.
   PubMed Web of Science ®Google Scholar
• Chiricozzi A, Burlando M, Caldarola G, et al. Ixekizumab effectiveness and safety in the treatment of moderate-to-severe plaque psoriasis: a multicenter, retrospective observational study. Am J Clin Dermatol. 2020;21(3):441–447. doi: 10.1007/s40257-019-00490-2.
   PubMed Web of Science ®Google Scholar
• Malagoli P, Dapavo P, Pavia G, et al. Real life long-term efficacy and safety of ixekizumab in moderate-to-severe psoriasis: a 192 weeks multicentric retrospective study-IL PSO (Italian landscape psoriasis). Dermatol Ther. 2022;35(8):e15608. doi: 10.1111/dth.15608.
   PubMed Web of Science ®Google Scholar
• Deza G, Notario J, Lopez-Ferrer A, et al. Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study. J Eur Acad Dermatol Venereol. 2019;33(3):553–559. doi: 10.1111/jdv.15288.
   PubMed Web of Science ®Google Scholar
• Gulliver W, Penney M, Power R, et al. Moderate-to-severe plaque psoriasis patients treated with ixekizumab: early real-world outcomes and adverse events. J Dermatolog Treat. 2022;33(1):354–360. doi: 10.1080/09546634.2020.1755009.
   PubMed Web of Science ®Google Scholar
• Pinter A, Puig L, Schäkel K, et al. Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO). J Eur Acad Dermatol Venereol. 2022;36(11):2087–2100. doi: 10.1111/jdv.18376.
   PubMed Web of Science ®Google Scholar
• Reich A, Reed C, Schuster C, et al. Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021. J Dermatolog Treat. 2023;34(1):2160196. doi: 10.1080/09546634.2022.2160196.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Körber A, Biermann M, et al. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatolog Treat. 2020;31(5):470–475. doi: 10.1080/09546634.2020.1746734.
   PubMed Web of Science ®Google Scholar
• Prevezas C, Katoulis AC, Papadavid E, et al. Short-Term correlation of the psoriasis area severity index, the nail psoriasis area severity index, and the dermatology life quality index, before and after treatment, in patients with skin and nail psoriasis. Skin Appendage Disord. 2019;5(6):344–349. doi: 10.1159/000499348.
   PubMed Web of Science ®Google Scholar
• Mattei PL, Corey KC, Kimball AB. Psoriasis area severity index (PASI) and the dermatology life quality index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies. J Eur Acad Dermatol Venereol. 2014;28(3):333–337. doi: 10.1111/jdv.12106.
   PubMed Web of Science ®Google Scholar
• Lynde C, Riedl E, Maul JT, et al. Comparative effectiveness of biologics across subgroups of patients with moderate-to-severe plaque psoriasis: results at week 12 from the PSoHO study in a real-world setting. Adv Ther. 2023;40(3):869–886. doi: 10.1007/s12325-022-02379-9.
   PubMed Web of Science ®Google Scholar
• Lockshin B, Cronin A, Harrison RW, et al. Drug survival of ixekizumab, TNF inhibitors, and other IL-17 inhibitors in real-world patients with psoriasis: the corona psoriasis registry. Dermatol Ther. 2021;34(2):e14808. doi: 10.1111/dth.14808.
   PubMed Web of Science ®Google Scholar
• Caldarola G, Chiricozzi A, Megna M, et al. Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study. Expert Opin Biol Ther. 2023;23(4):365–370. doi: 10.1080/14712598.2023.2193288.
   PubMed Web of Science ®Google Scholar
• Torres T, Puig L, Vender R, et al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891–904. doi: 10.1007/s40257-022-00722-y.
   PubMed Web of Science ®Google Scholar